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Copyright © 2010 JCBN Summary Soybean-derived phosphatidylserine (Soy-PS) is a phosphatidylserine made from
soybean lecithin by enzymatic reaction with L-serine. A double-blind, randomized controlled
study was conducted to investigate the effects of Soy-PS on the cognitive functions of the elderly
Japanese subjects with memory complaints. Seventy-eight elderly people with mild cognitive
impairment (50–69 years old) were randomly allocated to take Soy-PS (100 mg, 300 mg/day)
or placebo for 6 months. As a result, there was no difference in blood markers and vital signs
during Soy-PS treatment and any side effect caused by Soy-PS treatment was not observed.
Neuropsychological test scores were similarly increased in all groups including placebo group.
However, in the subjects with relatively low score at baseline, the memory scores in PS treated
groups were significantly increased against the baseline, while those of placebo group
remained unchanged. And the memory improvements in Soy-PS-treated groups were mostly
attributed to the increase in delayed verbal recall, a memory ability attenuated in the earliest
stage of dementia. In conclusion, Soy-PS used in this study is considered as safety food
ingredient and 6 months of Soy-PS supplementation could improve the memory functions of
the elderly with memory complaints.
Key Words:phosphatidylserine, soybean, elderly, memory functions, delayed verbal recall
Introduction
Phosphatidylserine (PS) is a member of the membrane
phospholipids that is especially abundant in the brain.
Because of its presence in the brain, effects of PS on the
central nervous system have been widely investigated [1–5].
Several clinical studies in the US and Europe have shown
that PS extracted from bovine cortex (BC-PS) improves
the cognitive function of the elderly [6–10] including
Alzheimer’s disease patients [8,  9] and people with age-
associated memory impairment (AAMI) [10]. However, the
use of BC-PS in medicine or dietary supplements is now
discouraged because of the risk of bovine spongiform
encephalopathy (BSE) [11]. In addition, only about 3 grams
of PS can be obtained from one bovine cortex, which is too
small for inexpensive supply.
Efforts to overcome these problems have led to the
development of soybean-derived PS (Soy-PS), a BSE risk-
free PS that is enzymatically made from soybean lecithin
[12]. Even though the acyl-groups of Soy-PS are quite
different from that of BC-PS, studies using drug-induced
amnesic and aged rodents have suggested that the effects of
Soy-PS on cognitive function are identical to that of BC-PS
[13–16].
However, the results of clinical studies using Soy-PS areEffects of Soybean Phosphatidylserine on Memory Functions
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controversial. In 1995, Gindin et al. [17] first reported a
clinical study of Soy-PS, where Soy-PS treatment (300 mg/
day for 3 months) on elderly people with AAMI improved
their Wechsler Memory test scores, especially in the compo-
nents of the test that evaluated visual memory. In their study,
the effect of Soy-PS was evident only in the subgroup of
subjects that had higher pre-treatment scores. Crook et al.
[18] reported that Soy-PS (300 mg/day for 12 weeks)
was effective in improving memory functions, such as
memorizing names and faces, of elderly people with AAMI.
Schreiber et al. [19] also reported similar results that Soy-PS
was most effective on memorizing faces.
Jorissen  et al. [ 20] performed a double-blind placebo-
controlled study to evaluate the efficacy of two different
doses of Soy-PS (300 or 600 mg/day for 12 weeks) on the
elderly with AAMI. Although various aspects of cognitive
function including memory, information processing speed,
selective attention and planning were measured, no difference
was found between placebo and Soy-PS treated groups even
with the higher dosage. Thus, it is still controversial whether
Soy-PS is effective for the elderly with memory impairment.
Furthermore, there has been no clinical study that evaluates
the effects of PS on memory impairment using Japanese
subjects.
To clarify whether Soy-PS is beneficial for cognitive
function of the elderly, we conducted a preliminarily open-
trial test in 2005 and found that 12 weeks of Soy-PS treat-
ment (300 mg/day) on elderly people with mild memory
impairment improved their scores on the revised version of
Hasegawa’s dementia scale (HDS-R) [21], a general test
used for diagnosis of dementia in Japan. Improvement was
especially evident in the delayed 3 words recall (DWR)
subtest. In addition, the effect of Soy-PS on DWR was
maintained for 12 weeks after the treatment period was
over. Based on these results, we next planned a double-blind,
placebo-controlled clinical study.
The present study was designed as a double-blind, placebo-
controlled trial to evaluate the efficacy of Soy-PS (100 mg
or 300 mg/day for 6 months) on the Japanese elderly with
mild memory impairment. For the selection of subjects
with mild memory impairment, we used the Rivermead
behavioral memory test (RBMT) [22], which focuses on
evaluating memory functions, especially everyday memory.
The treatment period of Soy-PS was set to 6 months, with
an additional 3-month follow-up period to see whether the
effects of Soy-PS would be maintained after discontinuing
its intake.
Materials and Methods
Subjects
Men and women living in the Tokyo metropolitan area,
ranging from 50 to 69 years old, with subjective memory
complaints were recruited from the volunteer bank of
clinical research organization (Huma R&D Co. Ltd., Tokyo).
Prior to the screening with neuropsychological tests, a
preliminary assessment was conducted at the recruiting
process to evaluate objective memory loss. Specifically,
the DWR subtest of HDS-R was done over the phone, and
those with 3 to 5 points out of 6 were selected. For further
screening, people who passed this preliminary assessment
took part in three neuropsychological tests (RBMT, HDS-R
and Mini-Mental State Examination: MMSE [23]) and a
medical interview, and those who fulfilled the selection
criteria became the subjects for this clinical study.
To screen out people with severe cognitive disorder who
need medical treatment, the selection criteria were set so as
to include people with mild memory impairment (RBMT
standard profile score<22) while excluding those with
possible dementia (HDS-R<21, MMSE<24).
Procedures for this study were approved by the institu-
tional review board of the testing agency, Tokyo Heart
Center (Tokyo, Japan). All subjects gave a written informed
consent before entering the study.
In total, 143 out of approximately 700 volunteers passed
the preliminary assessment on the phone, and 78 of them
fulfilled the selection criteria. Out of 78 subjects who
entered the study, 73 completed the study and 5 dropped out
(n = 3 in placebo, n = 1 in 100 mg Soy-PS and n =1  i n
300 mg Soy-PS). The reasons for dropout were either private
circumstances or health problems not related to PS treat-
ment. The design of this study and trial profile are shown in
Fig. 1.
Study design
The study was designed as a randomized, double-blind,
placebo-controlled, parallel-group trial. The subjects were
randomly divided into three groups (n = 28 in each group),
all similar in average age, sex, education year, neuro-
psychological test score, geriatric depression scale (GDS)
[24] score and everyday memory checklist (EMC) score
(Tables 1 and 5).
Within one month after the screening session, subjects
started taking their respective test samples: placebo, 100 mg
Soy-PS (PS100) or 300 mg Soy-PS (PS300), daily for 6
months. Six months of PS treatment was followed by a 3-
month follow-up period during which subjects took no
samples. For all measurements, the screening values were
used as baseline values.
The following examinations were conducted at baseline,
after 6 months of PS treatment and after 3 months of follow-
up period: HDS-R and MMSE for evaluating cognitive
function, GDS for evaluating depressive state, and blood/
urine tests for evaluating safety. In addition, RBMT and
EMC were conducted at baseline, at 1, 3 and 6 months of
PS treatment and after 3 months of follow-up.A. Kato-Kataoka et al.
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Treatment
Food-grade Soy-PS product (PS-20L, Yakult Honsha Co.
Ltd., Japan) produced from soybean lecithin by enzymatic
transphosphatidylation reaction was used in this study [25].
Test samples were taken in the form of soft gelatin capsules
(200 mg of content per capsule). Subjects took 3 capsules
after each meal, a total of 9 capsules per day, for 6 months.
The timing of Soy-PS intake was decided according to
previous papers [19, 20].
Nine capsules of PS300 contained 300 mg PS, 663 mg
phospholipids other than PS (PL), 702 mg middle-chain
triglycerides (MCT) and 135 mg vitamin E (VE). Nine
capsules of PS100 contained 100 mg PS, 863 mg PL,
702 mg MCT and 135 mg VE. Nine capsules of placebo
contained 963 mg PL, 702 mg MCT and 135 mg VE.
To prevent degradation of Soy-PS, a portion of the test
samples was sent to the subjects every month and was kept
under refrigeration at home.
Outcome measures
Primary outcome measures were cognitive functions
assessed by HDS-R, MMSE and RBMT. Secondary out-
comes were self-rating memory function assessed by EMC
and depressive state assessed by GDS. Blood and urine
parameters were also assessed for safety evaluation.
RBMT
RBMT is a standardized and validated test for memory
functions [22]. It consists of 12 subtests for evaluating
everyday memory such as of personal event, people’s
names, newspaper articles and places visited. The Japanese
version of RBMT was developed by Kazui et al. [26] in
2002. Standardized profile score is obtained by assigning a
Fig. 1. The study design and trial profile.
Table 1. Baseline characteristics of each treatment group
Values are mean ± SEM. The subjects in PS100 and PS300 groups
took 100 mg/d and 300 mg/d of Soy-PS for 6 months, respectively.
Placebo group took soybean lecithin containing no PS.
group Placebo PS100 PS300
Number of subjects 23 25 25
Number of male 12 12 14
Number of female 11 13 11
Age 59.6 ± 1.1 59.1 ± 1.1 59.6 ± 1.0
Education (year) 14.2 ± 0.4 13.4 ± 0.4 13.8 ± 0.4Effects of Soybean Phosphatidylserine on Memory Functions
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score of 0, 1, or 2 to each of the 12 subtests, summing up to
a maximum total score of 24 points. Degree of memory
impairment is categorized into 4 classes according to the
standardized profile score; 0–9: severely impaired, 10–16:
moderately impaired, 18–21: poor memory, >21: normal.
Four parallel forms (A, B, C and D) of the test were used in
the present study to avoid practice or learning effects.
HDS-R
HDS-R is a neuropsychological battery commonly used
for diagnosis of dementia in Japan [27], along with MMSE.
Those who score less than 21 points out of 30 are diagnosed
as “possible dementia”. The test assesses orientation,
memory, attention and verbal fluency. We especially focused
on the DWR subtest, because Soy-PS was most effective
on that subtest in our preliminary study [21]. In DWR, a
subject is presented with 3 unrelated words and is later asked
to recall them. For each word, the subject is given 2 points
for voluntarily recalling the word, and 1 point for recalling
the word with a hint (e.g. “vehicle” for the word “car” or
“animal” for the word “dog”). Two lists of 3 words were
prepared and the list was alternately used in this study to
minimize practice effect.
EMC
EMC is a questionnaire developed together with RBMT
for evaluating difficulties in daily life caused by memory
impairment [28]. It consists of a list of 13 memory problems
or difficult situations that likely happen in daily life.
Occurrence of each problem or situation is rated from 0
(none) to 3 (always), with a maximum score of 39 points.
Safety
Medical interview by a physician was conducted at every
evaluation point. Blood and urine tests were done at
baseline, end of PS treatment (6 months) and 3 months
after the end of treatment. Blood pressure and heart rate
were also measured as vital signs.
Data analysis
Data analyses were conducted according to the protocol
for statistical analysis pre-determined before key-opening.
Neuropsychological tests, EMC and GDS scores were
analyzed by Steel’s multi-comparison test against the base-
line score (within group) or against placebo (between
groups). Blood parameters and vital signs were analyzed
by Dunnett’s multi-comparison test against placebo group
for each evaluation point.
Stratified analyses based on RBMT score at baseline
were also conducted. Since the average score of healthy
Japanese adults in their 40s and 50s is reported to be
22.0 ± 2.0 points [27], the score below 1.5 standard devia-
tion from the average (= 19 points) was used as the stratifi-
cation criteria. Regarding stratified analyses, changes in
score against the baseline were used in order to correct for
initial differences among the groups. SAS 8.2 for Windows
was used for statistical analyses, with significance set at
p<0.05.
Safety of Soy-PS was evaluated by the deviation from the
normal range of blood and urine parameters, and its clinical
significance was judged by a physician.
Results
Safety
Throughout the test period, no adverse event was observed
in relation to sample intake. There was also no clinically
significant change in hematological and biological blood
parameters in all groups (Tables 2 and 3). Although a
significant difference in blood glucose level at 6 month
between placebo and PS100 group appeared, such difference
was not observed at higher dose (PS300) and therefore it is
considered clinically insignificant. Vital signs (Table 4) and
urine parameters (glucose, protein, occult blood and pH;
data not shown) didn’t show any significant changes.
Cognitive functions
Table 5 shows the score changes in RBMT. The scores
significantly increased against the baseline in all 3 groups,
with no difference between Soy-PS and placebo groups at
any evaluation point. In stratified analysis based on the
subjects’ degree of memory impairment at baseline, there
was still no difference between placebo and Soy-PS groups
either in the high-score subgroup (RBMT = 19 or more) or
the low-score subgroup (RBMT<19) (data not shown).
The total score of HDS-R increased during the treatment
period in all 3 groups, with no significant difference among
the groups (Table 5). However, after the 3-month follow-up
period, the score of the placebo group dropped back to its
baseline score, while the scores of 100PS and 300PS groups
were both maintained at a high level.
In the high-score subgroup, there was almost no score
change in the total score of HDS-R throughout the trial
(Fig. 2(A)). In contrast, total score of HDS-R in the low-score
subgroup significantly increased against the baseline by
Soy-PS treatment (Fig. 2(B)). There was a significant differ-
ence between placebo and 300PS groups after 3 months of
follow-up (p<0.05). The difference between placebo and
100PS also showed a significant trend (p = 0.05).
Fig. 3(A) shows the DWR score of HDS-R in the low-score
subgroup. The scores of Soy-PS treated groups increased
significantly against the baseline, and there were significant
differences between placebo and both Soy-PS groups after 3
months of follow-up (p<0.05 for 300PS, p =0 . 0 9  f o r
100PS). The magnitude of the score change in DWR was
quite similar to that of total score (Fig. 2(B)). It is apparentA. Kato-Kataoka et al.
J. Clin. Biochem. Nutr.
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Table 2. Changing in hematological blood parameters during the test period
Values are means (standard deviation). §The values at screening were used as baseline values. Subjects started taking the samples within
one month after screening. The follow-up period consisted of 3 months after finishing the 6 months of sample intake, during which
subjects took no sample.
0 month (baseline§) 6 months (treatment) 9 months (follow-up)
Placebo 
(n = 23)
PS100 
(n = 25)
PS300 
(n = 25)
Placebo 
(n = 23)
PS100 
(n =2 5 )
PS300 
(n = 25)
Placebo 
(n = 23)
PS100 
(n =2 5 )
PS300 
(n = 25)
White blood count 
(×109/L)
5.8 (1.3) 6.2 (1.4) 6.1 (1.1) 5.5 (1.2) 5.8 (1.2) 5.3 (1.2) 5.6 (1.2) 6.0 (1.4) 5.7 (1.3)
Platelet count 
(×1010/L)
24.1 (5.3) 24.7 (5.9) 24.3 (4.8) 23.8 (6.1) 24.2 (5.2) 22.8 (4.9) 23.8 (5.7) 24.8 (5.0) 23.5 (5.1)
Red blood count 
(×1012/L)
4.5 (0.4) 4.5 (0.3) 4.6 (0.3) 4.4 (0.3) 4.4 (0.3) 4.5 (0.3) 4.4 (0.3) 4.4 (0.4) 4.5 (0.3)
Hemoglobin 
(×10 g/L)
13.8 (1.0) 13.7 (1.0) 13.7 (1.0) 13.5 (1.0) 13.4 (1.1) 13.5 (1.2) 13.4 (0.8) 13.5(1.3) 13.5 (1.2)
Hematocrit 
(%)
42.9 (2.8) 42.5 (2.9) 42.7 (2.8) 42.0 (2.8) 41.6 (2.9) 42.0 (2.9) 41.3 (2.3) 41.4 (3.5) 41.8 (3.1)
Table 3. Changing in biological blood parameters during the test period
Values are means (standard deviation). §The values at screening were used as baseline values. Subjects started taking the samples within
one month after screening. The follow-up period consisted of 3 months after finishing the 6 months of sample intake, during which
subjects took no sample. #p<0.05 vs placebo group (Dunnett’s multi-comparison test). AST; Asparate amino transferase, ALT; Alanine
transaminase.
0 month (baseline§) 6 months (treatment) 9 months (follow-up)
Placebo 
(n =2 3 )
PS100 
(n =2 5 )
PS300 
(n = 25)
Placebo 
(n =2 3 )
PS100 
(n =2 5 )
PS300 
(n =2 5 )
Placebo 
(n = 23)
PS100 
(n =2 5 )
PS300 
(n =2 5 )
AST 
(units/L)
25.3 (15.3) 24.0 (6.6) 22.2 (9.3) 26.1 (18.7) 23.2 (6.6) 22.8 (7.5) 24.0 (14.6) 21.6 (5.1) 21.2 (8.5)
ALT 
(units/L)
30.7 (31.2) 24.7 (15.6) 23.0 (14.0) 26.7 (26.1) 20.2 (8.0) 23.3 (13.3) 26.2 (24.5) 22.2 (8.9) 22.1 (11.7)
Alkaline phosphatase 
(units/L)
225.7 (56.0) 212.8 (51.8) 230.1 (45.7) 228.3 (61.2) 220.6 (53.5) 214.2 (41.2) 220.2 (60.1) 218.7 (47.1) 215.4 (45.1)
Lactose dehydrogenase 
(units/L)
191.7 (39.6) 197.5 (37.0) 187.2 (23.7) 187.4 (40.9) 183.9 (24.7) 180.6 (26.0) 191.5 (41.9) 193.1 (25.6) 189.1 (18.9)
γ-GTP 
(units/L)
33.9 (17.8) 29.7 (17.5) 34.9 (30.6) 32.4 (21.1) 27.8 (19.8) 32.8 (31.4) 30.6 (18.9) 27.9 (18.0) 30.8 (27.8)
Creatine phosphokinase 
(units/L)
121.6 (54.8) 166.3 (115.1) 115.3 (57.5) 125.1 (41.4) 149.8 (114.1) 116.5 (56.4) 128.2 (55.9) 175.0 (153.7) 113.5 (45.7)
Creatinine 
(mg/dL)
0.7 (0.1) 0.8 (0.2) 0.7 (0.2) 0.7 (0.1) 0.7 (0.2) 0.7 (0.2) 0.7 (0.1) 0.8 (0.1) 0.7 (0.2)
Blood urea nitrogen 
(mg/dL)
14.9 (2.9) 14.7 (3.6) 14.5 (2.6) 15.3 (3.4) 15.1 (4.1) 14.3 (2.8) 15.7 (3.7) 15.9 (3.7) 15.6 (3.1)
Uric acid 
(mg/dL)
5.2 (1.3) 5.7 (1.4) 4.9 (1.3) 5.3 (1.5) 5.5 (1.4) 5.1 (1.4) 5.2 (1.4) 5.6 (1.5) 4.9 (1.4)
HDL-cholesterol 
(mg/dL)
65.5 (14.7) 71.9 (14.7) 65.1 (14.8) 65.2 (15.3) 72.1 (14.6) 65.1 (11.5) 63.3 (16.1) 69.3 (13.6) 63.2 (13.5)
LDL-cholesterol 
(mg/dL)
141.0 (38.2) 128.3 (25.9) 134.3 (34.7) 130.5 (29.1) 127.7 (25.4) 142.3 (36.9) 130.9 (31.6) 126.3 (28.7) 134.2 (31.9)
Triglyceride 
(mg/dL)
111.9 (60.8) 89.6 (34.8) 116.1 (63.6) 121.6 (92.0) 104.7 (56.5) 113.0 (48.0) 124.0 (103.7) 99.8 (35.5) 125.7 (73.9)
Blood glucose 
(mg/dL)
91.3 (10.7) 86.2 (10.8) 87.5 (6.1) 94.7 (13.3) 86.9 (7.5)# 89.6 (8.7) 94.4 (11.3) 91.5 (9.4) 93.2 (11.0)Effects of Soybean Phosphatidylserine on Memory Functions
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that the change in total score was mainly attributed to the
change in DWR subtest score. In fact, there were no signifi-
cant changes in other subtest scores of HDS-R (data not
shown).
Although the degree of change was smaller, the same
trend was observed in the DWR subtest of MMSE (Fig. 3(B)).
The score significantly increased against the baseline only
in Soy-PS treated groups, and there were significant differ-
ences between placebo and Soy-PS groups (p<0.05 for both
100PS and 300PS). There was almost no change in other
subtest scores of MMSE (data not shown).
Subjective changes in memory and mood
Both GDS and EMC scores showed a gradual decrease in
all 3 groups, but there was no significant difference among
the groups at any evaluation point (Table 5).
Discussion
This double-blind, placebo-controlled study is the first
clinical trial which demonstrates that Soy-PS has positive
effects on cognitive performance in Japanese subjects with
memory complaints.
The effect of Soy-PS was dominant in verbal list recall
tests such as the DWR of HDS-R and MMSE. This result
Table 4. Changing in vital signs during the test period
Values are means (standard deviation). §The values at screening were used as baseline values. Subjects started taking the samples within
one month after screening. The follow-up period consisted of 3 months after finishing the 6 months of sample intake, during which
subjects took no sample.
0 month (baseline§) 6 months (treatment) 9 months (follow-up)
Placebo 
(n = 23)
PS100 
(n =2 5 )
PS300 
(n =2 5 )
Placebo 
(n = 23)
PS100 
(n =2 5 )
PS300 
(n =2 5 )
Placebo 
(n =2 3 )
PS100 
(n =2 5 )
PS300 
(n =2 5 )
Diastolic pressure 
(mm Hg)
84.1 (10.6) 82.2 (12.9) 85.2 (11.3) 72.7 (13.8) 71.1 (10.9) 71.3 (11.0) 69.0 (12.5) 71.8 (10.7) 68.4 (10.0)
Systolic pressure 
(mm Hg)
129.1 (16.5) 124.8 (18.8) 128.2 (14.4) 123.9 (19.8) 118.7 (14.7) 122.9 (14.9) 123.3 (16.8) 121.1 (15.4) 122.6 (13.8)
Heart rate 
(bpm)
70.0 (7.7) 72.4 (9.7) 70.6 (7.6) 71.1 (10.2) 71.7 (9.5) 71.7 (11.0) 71.7 (8.0) 74.1 (9.0) 72.1 (9.3)
Table 5. Results of the neuropsychological tests and the questionnaires of memory and mood
Values are mean ± SEM. §The values at screening were used as baseline values. Subjects started taking the samples within one month after
screening. The follow-up period consisted of 3 months after finishing the 6 months of sample intake, during which subjects took no
sample. *p<0.05, **p<0.01, ***p<0.001 vs baseline, #p<0.05 vs placebo group (Steel’s multi-comparison test).
Group
0 month 
(baseline§)
1 month 
(treatment)
3 months 
(treatment)
6 months 
(treatment)
9 months 
(follow-up)
RBMT
Placebo 18.3 ± 0.52 18.3 ± 0.91 20.4 ± 0.57** 22.2 ± 0.46*** 22.2 ± 0.48***
PS100 18.4 ± 0.59 19.4 ± 0.44 20.1 ± 0.44 22.3 ± 0.29*** 22.6 ± 0.24***
PS300 18.0 ± 0.49 19.5 ± 0.44 19.1 ± 0.50 21.6 ± 0.32*** 21.6 ± 0.41***
HDS-R
Placebo 28.0 ± 0.38 — — 29.1 ± 0.25* 28.5 ± 0.29
PS100 27.8 ± 0.42 — — 29.2 ± 0.22* 29.2 ± 0.19*
PS300 27.4 ± 0.32 — — 28.4 ± 0.31* 28.6 ± 0.35**
MMSE
Placebo 27.9 ± 0.38 — — 28.5 ± 0.37 28.2 ± 0.35
PS100 27.7 ± 0.39 — — 29.0 ± 0.26* 29.2 ± 0.29** #
PS300 27.6 ± 0.39 — — 28.0 ± 0.30 28.2 ± 0.35
EMC
Placebo 29.1 ± 1.20 26.8 ± 1.13 26.1 ± 1.12 24.6 ± 0.90** 25.1 ± 1.09*
PS100 28.8 ± 1.24 28.0 ± 1.26 27.8 ± 1.49 27.4 ± 1.25 27.2 ± 1.46
PS300 28.7 ± 1.04 27.0 ± 0.97 26.3 ± 1.04 26.0 ± 1.02 24.6 ± 0.98*
GDS
Placebo 10.7 ± 1.05 — — 7.1 ± 0.91* 5.2 ± 0.81***
PS100 10.7 ± 1.10 — — 8.7 ± 1.21 7.1 ± 1.02*
PS300 11.4 ± 1.51 — — 8.9 ± 1.38 8.1 ± 1.35A. Kato-Kataoka et al.
J. Clin. Biochem. Nutr.
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reinforces our preliminary study in which the DWR score of
HDS-R notably improved by Soy-PS treatment for 3 months
[21]. The improving effects of PS on verbal list recall tests
have also been consistently observed in many previous
studies [29]. For example, a large clinical study of 494
elderly patients with moderate to severe cognitive decline
showed that taking 300 mg of BC-PS daily for 6 months
significantly improved their performance on the word list
recall test [7]. The effect of BC-PS on list recall test was
also observed in a study of subjects with AAMI [10]. The
result of our present study is well consistent with these
previous studies of BC-PS.
On the other hand, Jorissen et al. [ 20] reported that
Soy-PS treatment was ineffective for word list recall. There
are differences in study design such as the selection criteria
for subjects and the duration of treatment, and what has
caused the contradictory result is unclear. Nonetheless, we
demonstrated that Soy-PS is also effective on the word list
recall as BC-PS.
It has been reported that delayed verbal recall is the most
effective cognitive domain for discriminating the earliest
stage of dementia (early Alzheimer’s disease and mild
cognitive impairment) from normal aging [30, 31]. Therefore
the present result that Soy-PS was effective on delayed
verbal recall tests suggests that Soy-PS is effective for
treating the earliest stage of dementia. The scores of the
subtests of HDS-R and MMSE other than the verbal delayed
recall were already high at baseline. Thus, Soy-PS is
probably more suitable for subjects with memory complaints
rather than for subjects with advanced dementia who need
medical treatment.
RBMT was also conducted to evaluate the effects of
Soy-PS on everyday memory. RBMT includes subtests for
evaluating facial recognition and name-face association,
Fig. 2. Effect of Soy-PS on HDS-R performance in high-score
and low-score subgroups. Subjects were divided into
two subgroups based on their baseline RBMT score. (A)
High-score subgroup (RBMT score = 19 or more). (B)
Low-score subgroup (RBMT score<19). Values are
means ± SEM and shown as changes in score against the
baseline. **p<0.01, ***p<0.001 vs baseline, $p<0.1,
#p<0.05 vs placebo group (Steel’s multi-comparison test).
Fig. 3. Effect of Soy-PS on DWR subtest of HDS-R and MMSE
in the low-score subgroup (RBMT score<19 at baseline).
(A) DWR subtest of HDS-R. (B) DWR subtest of
MMSE. Values are means ± SEM and shown as changes
in score against the baseline. *p<0.05, **p<0.01,
***p<0.001 vs baseline, $p<0.1,  #p<0.05 vs placebo
group (Steel’s multi-comparison test).Effects of Soybean Phosphatidylserine on Memory Functions
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which have been reported to improve by PS treatment
[18, 19]. However, the effect of Soy-PS on such tests was
not observed in the present study. One of the reasons may be
that the subjects already marked high scores at baseline and
there was no room for further improvement. Since RBMT is
intended for people with certain memory impairment, its
level of difficulty was perhaps not appropriate for the
subjects of this study whose memory functions were nearly
normal.
Ceiling effects were also observed in HDS-R and MMSE.
As mentioned above, the score of each subtest other than
DWR was already high at baseline and there was no room
for improvement. Consequently, the effect of Soy-PS on
HDS-R and MMSE was only apparent in the low-score
subgroup. The effects of Soy-PS may be observed more
clearly by using a more sensitive neuropsychological test
that enables the detection of subtle or mild memory impair-
ment.
In this study, we tested two dosages of Soy-PS, 100 and
300 mg/day, to determine the optimal amount of intake for
the elderly with memory complaints. The memory-improving
effect of Soy-PS was equally observed in both groups.
Although it is unclear whether taking 100 or 300 mg/day of
Soy-PS for a period of less than 6 months exerts the same
effect, Crook et al. [18] have reported that 100 or 300 mg/
day of Soy-PS intake improved memory functions after 3
weeks and 12 weeks of treatment.
We did not measure blood PS levels in the present study,
but some pharmacokinetics studies show that orally admin-
istrated PS can be rapidly absorbed and carried to the brain
through the blood brain barrier [32]. Our previous observa-
tion that the intracerebroventricular injection of Soy-PS
improved memory impairment of amnesic mice [15] suggests
that Soy-PS could function in the brain directly.
Another study has shown that the oral administration of
Soy-PS ameliorated the memory impairment of aged rats
[16]. In these animals the acetylcholine release and Na+,
K+-ATPase activity of the synaptosome were also improved.
This suggests the involvement of cholinergic transmission,
energy metabolism or the status of membrane potential of
nerve cells in the mechanism of PS action. It is also reported
that PS inhibited lipid peroxidation induced by inflam-
matory oxidants derived from neutrophil myeloperoxidase
[33]. PS also decreased the production of reactive oxygen
species from microglia induced by amyloid β peptide [34].
The anti-oxidative and/or anti-inflammatory properties of
PS may be important for its nootropic mechanism. It is
interesting to mention that astaxanthin, a potent antioxidant,
improved delayed recall of subjects with memory complaints
[35].
The effect of Soy-PS became more evident after the 3-
month follow-up period rather than just after 6 months of
Soy-PS treatment. A similar result has been reported by
Amaducci et al., [8] who evaluated the effects of BC-PS
(200 mg/day for 3 months) on the cognitive function of 142
Alzheimer’s disease patients. In their study, the effect of
PS was more evident after the post-treatment follow-up
period rather than immediately after 3 months of PS treat-
ment. They proposed that PS may cause structural neuronal
changes rather than transient metabolic changes, and
therefore the beneficial effect might be maintained even
after cessation of treatment.
As a supportive evidence, it has been reported that
prolonged oral PS treatment elicits structural neuronal
changes in aged rats [36]. In summary, the dendritic spine
density of aged rats treated with BC-PS was maintained at
the same level as that of young rats, whereas non-treated
aged rats showed a significant decrease in dendritic density,
with a mean loss of about 10%. It is unclear if such structural
changes occurred in the subjects of our present study, but
prolonged effects of PS have also been shown by other
clinical studies using BC-PS, such as in AAMI subjects [10]
and in early Alzheimer’s disease patients [9].
There is a concern that the placebo sample used in this
study contained some components that have been reported to
have a memory-improving function, such as phosphatidyl-
choline [37], MCT [38] and VE [39]. Although the amount
of intake was supposedly much lower than the effective
dosage of these components, there is a possibility that the
placebo sample actually improved memory function by
interacting synergistically and eliciting transient metabolic
changes.
Conclusions
The oral administration of Soy-PS for 6 months improved
memory function, especially delayed recall, in the elderly
with memory complaints. This effect was equally observed
at both low dose (100 mg/day) and high dose (300 mg/day).
The safety of Soy-PS was also confirmed. Since delayed
recall is thought to be one of the cognitive functions
impaired at the earliest stage of dementia, Soy-PS may serve
as a desirable supplement for preventing dementia develop-
ment in people with memory complaints. In the future, the
memory-improving effects of Soy-PS may be indicated
more clearly by reconsidering the study design.
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